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Abstract: BACKGROUND We aimed to develop a gene expression-based prognostic signature for isoci-
trate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblas-
toma clinical trial populations. METHODS Samples were collected from newly diagnosed patients with
IDH wild-type glioblastoma in the ARTE, TAMIGA, EORTC 26101 (referred to as ”ATE”), AVAglio,
and GLARIUS trials, or treated at UCLA. Transcriptional profiling was achieved with the NanoString
gene expression platform. To identify genes prognostic for overall survival (OS), we built an elastic net
penalized Cox proportional hazards regression model using the discovery ATE dataset. For validation
in independent datasets (AVAglio, GLARIUS, UCLA), we combined elastic net-selected genes into a
robust z-score signature (ATE score) to overcome gene expression platform differences between discovery
and validation cohorts. RESULTS NanoString data were available from 512 patients in the ATE dataset.
Elastic net identified a prognostic signature of 9 genes (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L,
PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores to the ATE score conserved
the prognostic value of the genes. The ATE score was prognostic for OS in the ATE dataset (P < 0.0001),
as expected, and in the validation cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.02; UCLA, P = 0.004).
The ATE score remained prognostic following adjustment for O6-methylguanine-DNA methyltransferase
(MGMT) promoter methylation status and corticosteroid use at baseline. A positive correlation between
ATE score and proneural/proliferative subtypes was observed in patients with MGMT non-methylated
promoter status. CONCLUSIONS The ATE score showed prognostic value and may enable clinical trial
stratification for IDH wild-type glioblastoma.
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Background. We aimed to develop a gene expression-based prognostic signature for 
isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets 
representative of glioblastoma clinical trial populations. 
Methods. Samples were collected from newly diagnosed patients with IDH wild-type 
glioblastoma in the ARTE, TAMIGA, EORTC 26101 (referred to as ‘ATE’), AVAglio, 
and GLARIUS trials, or treated at UCLA. Transcriptional profiling was achieved with the 
NanoString gene expression platform. To identify genes prognostic for overall survival 
(OS), we built an elastic net penalized Cox proportional hazards regression model using 
the discovery ATE dataset. For validation in independent datasets (AVAglio, GLARIUS, 
UCLA), we combined elastic net-selected genes into a robust z-score signature (ATE 
score) to overcome gene expression platform differences between discovery and 
validation cohorts.  
Results. NanoString data were available from 512 patients in the ATE dataset. Elastic net 
identified a prognostic signature of nine genes (CHEK1, GPR17, IGF2BP3, MGMT, 
MTHFD1L, PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores 
to the ATE score conserved the prognostic value of the genes. The ATE score was 
prognostic for OS in the ATE dataset (P < 0.0001), as expected, and in the validation 
cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.02; UCLA, P = 0.004). The ATE score 
remained prognostic following adjustment for MGMT promoter methylation status and 
corticosteroid use at baseline. A positive correlation between ATE score and 





Conclusions. The ATE score showed prognostic value and may enable clinical trial 
stratification for IDH wild-type glioblastoma.  
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Key Points  
1. We identified a new RNA signature predictive of OS in IDH wild-type glioblastoma 
2. Prognostic value was maintained after adjustment for several clinical variables 
3. The signature may enable trial stratification for IDH wild-type glioblastoma 
 
Importance of the Study  
There has been limited success in identifying prognostic molecular markers for IDH 
wild-type glioblastoma, or in the development of new therapies to extend OS for these 
patients. We pooled samples from clinical trial datasets representative of glioblastoma 
clinical trial populations, and used transcriptional profiling and elastic net penalized Cox 
proportional hazards regression to develop a prognostic expression signature. We 
identified a signature of nine genes as prognostic for OS in the discovery dataset (P < 
0.0001), and validated the prognostic association in independent cohorts (AVAglio, P < 
0.0001; GLARIUS, P = 0.02; UCLA, P = 0.004). This novel signature can be measured 
in routine diagnostic FFPE samples. Prognostic value was maintained after adjustment 
for MGMT promoter methylation status and corticosteroid use status at baseline, 




wild-type glioblastoma. Future studies are required to further validate the signature’s 






Diagnosis of brain tumors has evolved from using purely histologic criteria to 
incorporating both histologic and molecular features.1 The current classification system 
recognizes glioblastoma with or without mutations in the isocitrate dehydrogenase genes 
(IDH1 or IDH2) as distinct and prognostically separate entities.1 Recently, the 
introduction of global methylation profiles led to further refinement and improvement of 
the classification.2 Methylation of the O-6-methylguanine-DNA methyltransferase gene 
(MGMT) promoter is associated with prolonged overall survival (OS) in glioblastoma 
treated with alkylating agents,3 although routine testing remains challenging due to 
variations in detection methods and cutoff definitions.4,5 
The past decade has seen little progress in the development of new therapeutic 
modalities that extend OS for patients with glioblastoma, or in the identification of 
methods to predict which patients will fare better than others with current standard of 
care. For newly diagnosed glioblastoma, current standard of care, comprising surgical 
resection followed by temozolomide and radiotherapy, was established in 2005 in a 
randomized phase III trial.6 Results from the trial also showed an association between 
hypermethylation of the MGMT promoter and improved benefit from alkylating 
chemotherapy,7 yet MGMT promoter methylation testing is still not routinely performed.  
Understanding of molecular features of tumors associated with poor outcome may 
aid efforts to develop new pharmacologic therapies. While large-scale sequencing 
approaches have revealed mutations that are likely drivers of oncogenesis in discrete 
subsets of glioblastoma cases,8-10 with the exception of mutations in IDH1/IDH2, driver 




Studies seeking to identify prognostic molecular markers for IDH wild-type glioblastoma 
have yielded limited results.11-15 MGMT promoter methylation has been shown to predict 
outcome of patients with glioblastoma undergoing radiotherapy combined with 
temozolomide or temozolomide alone.7,16,17 RNA expression subtypes of glioblastoma 
(proneural, proliferative, and mesenchymal glioblastomas) have been well described;18 
however, prognostic value for these subtypes has not been validated within the IDH wild-
type tumor population. Similarly, studies reporting prognostic expression signatures 
derived from analysis of The Cancer Genome Atlas (TCGA) glioblastoma dataset have 
not demonstrated prognostic value in sample sets confined to IDH wild-type cases.9,19-23 
Recent trials have accrued patients according to MGMT promoter methylation or 
epidermal growth factor receptor amplification status.24,25  
To develop a gene expression-based prognostic signature for IDH wild-type 
glioblastoma with markers that can be assessed in formalin-fixed paraffin-embedded 
(FFPE) tumor samples, we integrated several large datasets from archival samples 
obtained from glioblastoma clinical trial patients with well-defined treatments, 
comprehensive annotation, and gene expression data from a common platform.  
 
Patients and Methods  
Study Design and Sample Collection 
This project was reviewed and agreed in collaboration with Genentech and the 




samples were collected from patients with newly diagnosed IDH wild-type glioblastoma 
who provided written informed consent to participate in exploratory translational research 
within the ARTE,26 TAMIGA,27 EORTC 26101,28 (hereafter collectively termed ‘ATE’), 
AVAglio,29 and GLARIUS30 trials. Additional samples from patients with newly 
diagnosed IDH wild-type glioblastoma treated in the upfront setting with standard of 
care, with or without experimental agents, were obtained from the University of 
California, Los Angeles (UCLA). All samples were taken from patients at initial surgical 
resection before they were treated with any other therapeutic intervention. Patient 
baseline characteristics are summarized in Table 1.  
NanoString Gene Expression Data Generation 
RNA was extracted from 1068 FFPE patient samples and run on a customized 
glioblastoma panel comprised of 814 features, as previously described,31 on the 
NanoString gene expression platform (NanoString Technologies, Seattle, WA). As the 
512 samples from the ATE trials were all analyzed in the same laboratory on a single 
NanoString code set and processed using a shared control specimen for normalization, 
data from these samples could be readily pooled. Samples from AVAglio, GLARIUS, 
and UCLA were processed with a new NanoString code set targeting the same 814 
features.  
The raw probe intensities were corrected for background using blanks (water) and 
then normalized using the NanoStringQCPro package in R.32 Raw data were pre-
processed using functions from NanoStringQCPro R package: positive control 




normalization (median normalization). Prior to prognostic signature analysis, sample-
wise normalization was performed by transforming counts to the log2 scale and 
subtracting the sample-wise mean expression of housekeeping genes. Genes were 
subsequently centered and scaled across the complete dataset (ATE, AVAglio, 
GLARIUS, and UCLA) to convert gene expression to z-scores. 
Gene Expression Analysis and Subtype Classification 
Quantile normalized gene expression data for 441 TCGA glioblastoma samples10 
processed on an Affymetrix Human Exon 1.0 ST Array were downloaded from 
Firebrowse (firebrowse.org; version 2016 01 28). Gene ontology (GO) term enrichment 
was performed with the goanna function implemented in the limma R package (version 
3.83.3).33 Hierarchical clustering was performed using the R ward.D2 method. The 
dendrogram was visualized using a custom R script. The Phillips subtypes were assigned 
to the validation and discovery datasets using the Partitioning Around Medoids classifier 
described previously.34,35 
Prognostic Signature Analysis using Elastic Net Regression 
Using OS data, we built an elastic net penalized Cox proportional hazards regression 
model using the glmnet R package with alpha fixed at 0.5 (and lambda selected via cross-
validation using the ‘1 se’ approach). For validation of the signature in independent 
datasets, we used only the signs of the elastic net fitted coefficients, rather than the actual 
coefficient values, to calculate an unweighted averaged z-score signature (ATE score) per 
patient. This averaged z-score approach was intended to minimize the impact of batch 





Univariate and multivariate survival analyses were performed using OS data for samples 
from each trial separately (ATE, AVAglio, and UCLA datasets) to identify potential 
treatment effects. Although EORTC 26101, in contrast to the other trials, recruited 
patients in the second-line setting, the survival times were calculated from the primary 
diagnosis. Since no treatment effect was observed in the trials of the validation 
(AVAglio, GLARIUS, and UCLA) or discovery (ATE) cohorts, we pooled all samples 
from the discovery datasets for elastic net penalized Cox proportional hazards regression 
analysis. Factors prognostic in univariate analyses of the ATE discovery dataset (age, 
sex, corticosteroid use, surgical status, Karnofsky performance status score, and MGMT 
status) were added as covariates to ATE status (defined as either a high or low ATE score 
split by the median) in multivariate models of OS in each cohort. Each of the models was 
fitted using Cox proportional hazards and visualized by Kaplan–Meier plots. To assess 
whether the prognostic effect of the ATE score was independent of Phillips subtype, a 
multivariate Cox proportional hazards analysis was conducted for each cohort; this model 
included ATE status, Phillips subtype, and other variables found to be significant in 
univariate analyses (Supplementary Table 1). All data were used for the survival analysis; 
however, for visualization purposes, we limited the horizontal axis to 100 months.    
 
Results 




NanoString gene expression data available from patients enrolled in three of six cohorts 
(ARTE, n = 50; TAMIGA, n = 99; and EORTC 26101, n = 279; collectively referred to 
as ‘ATE’) were used as the discovery dataset to identify a prognostic signature for OS. 
Elastic net penalized Cox proportional hazards regression analysis revealed a prognostic 
signature in the ATE dataset composed of nine genes (CHEK1, GPR17, IGF2BP3, 
MGMT, MTHFD1L, PTRH2, SOX11, S100A9, and TFRC, referred to as ‘the elastic net’ 
score; Fig. 1A). We also looked for additional genes for which expression was highly 
correlated (Pearson correlation |r| >0.65) with that of one or more of the signature genes, 
to provide better insight into the underlying biology. We did this first using NanoString 
gene expression data for the ATE cohort (Supplementary Fig. 1A), and next using 
microarray data for the TCGA glioblastoma cohort, which, unlike NanoString, represents 
the full transcriptome (Supplementary Fig. 1B). Within the NanoString gene expression 
data, three elastic net signature markers, GPR17, IGF2BP3, and SOX11, were correlated 
with two previously identified markers of proneural subtype glioblastoma (DLL3 and 
KLRC3; Supplementary Fig. 1A).18 In addition, expression of CHEK1 correlated with 
that of the proliferative subtype marker CENPK. The major GO terms associated with the 
expanded gene set from the whole-transcriptome TCGA data included mitotic cell cycle, 
nucleic acid binding, myelination, mitochondrion, negative regulation of JNK cascade, 
and immune response. Results for the expanded gene set from the ATE data were similar, 
though lacking the JNK cascade GO term, possibly due to the reduced transcriptome 
coverage of the NanoString panel. As expected, the elastic net score was prognostic for 
OS in the combined ATE dataset (P < 0.0001; Fig. 1B), with the effect size mainly driven 




Generalizing the Signature to Enable Application in Other Settings 
Although all studies employed NanoString gene expression platforms, batch effects 
across the studies presented challenges for direct application of a signature learned from 
studies employing one code set to those employing a different one. To address this, we 
calculated per-gene z-scores for the nine elastic net signature genes and averaged the 
results to make a new, more robust signature (hereafter known as the ‘ATE score’). This 
new ATE score correlated with the elastic net score (Supplementary Fig. 2), and it was 
also prognostic in the ATE cohort (P < 0.0001; Fig. 2A). Moreover, evaluating the ATE 
score after adjusting for MGMT promoter methylation status (HR 3.09; Fig. 2B), or for 
MGMT promoter methylation status and corticosteroid use at study entry, which are 
known prognostic factors35 (HR 3.29; Fig. 2C; Supplementary Table 1), achieved a 
similar effect size as the original elastic net score (HR 3.34; Fig. 1B).  
In addition to the residual analysis approach in Figs. 2B and 2C, we also used a 
nested-models approach to show that the prognostic information provided by the ATE 
score was not redundant with that of MGMT status and/or corticosteroid use. When 
comparing a model with the ATE score to a model with the ATE score plus MGMT 
promoter methylation status, we found significantly enhanced prognostic value from the 
addition of MGMT promoter methylation status (chi-squared P < 0.0001). The same was 
true for the addition of corticosteroid use (on or off) to a model with the ATE score plus 
MGMT promoter methylation status (P < 0.001). We also tested a model with MGMT 
status only against a model with MGMT status and the ATE score; we found that addition 
of the signature significantly improved prognostic value (P < 0.0001). The same was true 




and corticosteroid use (P < 0.0001). Thus, the ATE score provides a statistically 
significant increase in explanatory power beyond that of established prognostic factors, 
and conventional prognostic factors also add value to the ATE score.  
Validation of the Prognostic Signature in Independent Datasets 
Our results were validated in three independent cohorts: the AVAglio trial (n = 339), the 
UCLA glioblastoma collection (n = 154), and the GLARIUS MGMT non-methylated trial 
(n = 123). The ATE score was significantly prognostic for OS in each of these cohorts, 
both with (P < 0.0001, P = 0.004, and P = 0.02, respectively; Fig. 3) and without (P = 
0.002 for AVAglio, P = 0.03 for UCLA; Supplementary Fig. 3) adjustment for MGMT 
promoter methylation status.  
When including a full set of clinical variables that showed significant association 
with OS in univariate analyses of the ATE dataset (age, sex, surgical status, MGMT 
promoter methylation status, and, for ATE and AVAglio cohorts, corticosteroid use), the 
ATE score remained significantly prognostic for ATE, AVAglio, and UCLA, though not 
for GLARIUS (Fig. 4).  
Higher median signature scores were observed in tumors of the proliferative and 
proneural Phillips subtypes in patients with MGMT non-methylated promoter status 
across all cohorts (Fig. 5). This trend was also observed for MGMT methylated samples 
for ATE and AVAglio cohorts. Importantly, average ATE score did not simply 
recapitulate prognostic effects attributable to the Phillips subtypes. In multivariate 
modeling considering Phillips subtype together with variables found to be significant in 




ATE, AVAglio, and UCLA (P < 0.001, P = 0.002, and P = 0.019 respectively; 
Supplementary Fig. 4). 
To determine whether the signature is heterogeneously expressed within a single 
tumor, we looked at the expression of the nine signature genes and the ATE score in 
recently published single-cell data from Neftel et al., obtained from adult IDH wild-type 
tumors, including both tumor cells and other cell types from the tumor 
microenvironment.36 Neftel et al. grouped their data into four major cell types, and we 
found that the fraction of cells with detectible expression, as well as median expression, 
was highest in the macrophage and/or malignant (i.e., tumor) cell groups relative to the 
other cell types captured in their study (Fig. 5B and Fig. 5C).   
 
Discussion 
We aimed to determine whether a prognostic expression signature could be developed for 
newly diagnosed IDH wild-type glioblastoma using samples from several datasets that 
are representative of existing glioblastoma clinical trial patient populations.26-30 We 
identified a z-score signature (ATE score) predictive of OS in a large dataset from three 
pooled patient populations, and validated the prognostic value of the signature in three 
additional independent datasets. The newly described signature comprised nine gene 
expression markers (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L, PTRH2, SOX11, 
S100A9, and TFRC) that could be measured in routine FFPE diagnostic samples. 
Prognostic value was maintained after adjustment for MGMT promoter methylation status 




variables, suggesting that the signature could be used as an aid in trial design for patients 
with IDH wild-type glioblastoma. For example, the ATE score could be used to balance 
poor- and good-prognosis patients in trials of IDH wild-type glioblastoma, avoiding 
molecular bias, or as a stratification factor in larger trials. Depending on the scope of the 
trial, such stratification could be done prospectively at inclusion or post hoc. 
Association was seen between the signature and previously described expression 
subtypes,9,18 especially within MGMT non-methylated samples. Specifically, a positive 
association was observed between high signature scores and both proliferative and 
proneural subtypes. Of the nine genes in the signature, only CHEK1 and GPR17 showed 
significant differential subtype expression (upregulated in proliferative and proneural, 
respectively) in the original dataset used to define Phillips subtypes.18 Consistent with 
this, these two signature genes plus IGF2BP3 and SOX11 correlated with expression of 
previously identified Phillips subtype markers. However, the majority of the genes in the 
signature were not related to previously described glioblastoma expression subtypes. 
Furthermore, the signature showed a significant association with outcome across multiple 
validation datasets in multivariate models that included previously described subtypes. 
Thus, there is significant prognostic value in the signature that is independent of 
previously described subtypes, and the signature represents a novel and complementary 
prognostic molecular classifier of outcomes in newly diagnosed IDH wild-type 
glioblastoma.  
Interestingly, in multivariate models, the signature association with OS was 
significant in AVAglio and UCLA datasets, but not in GLARIUS. The direction of effect 




significance was not achieved. This may be a consequence of the smaller sample size in 
GLARIUS, or the fact that GLARIUS was unique in enrolling only patients with MGMT 
non-methylated promoter status.  
The ATE score showed statistically significant, though relatively modest, effect 
size (HR 1.15–1.31 in the three significant multivariate models) compared with the effect 
size seen for MGMT promoter methylation status. Importantly, in all datasets examined, 
the Kaplan–Meier curves obtained in signature-only analyses separated early and 
remained separate throughout their course, suggesting that the ATE score does more than 
identify small subsets of patients who are likely to have especially poor or good outcome.  
As the majority of patients in our investigation received standard-of-care 
treatment in the upfront setting, we cannot say definitively whether the ATE score 
predicts survival outcomes in the absence of standard treatment with temozolomide and 
radiation. No significant interactions were observed between the signature and treatment 
arm in any of the trials included in the analysis. Thus, there is no evidence to suggest that 
the ATE score is predictive of response to any of the experimental interventions tested in 
these trials, e.g., bevacizumab.  
Consistent with the expectation that subsets of genes identified by elastic net each 
contribute to the prognostic value of the ATE score independently, examination of the 
described functions of the proteins derived from these genes revealed a pattern of non-
overlapping biologies. MGMT promoter methylation has been extensively studied as a 
marker in glioblastoma, and has been reported to predict both response to temozolomide 




irradiation.6,17,31 MGMT and CHEK1 are both involved in DNA damage repair, but while 
MGMT plays a direct role in repair of alkylated DNA, CHEK1 plays a role in response to 
radiation-induced damage.37,38 It is thus conceivable that enhanced expression of these 
two genes confers escape from current standard-of-care treatment, promoting inferior 
survival. Both SOX11 and GPR17 are key regulators of differentiation within the central 
nervous system, but the role of SOX11 is confined to neurogenesis,39-41 and that of 
GPR17 to gliogenesis.42-44 The metabolic proteins identified in the ATE score (TFRC, 
MTHFD1L, and PTRH2) influence separate metabolic processes and appear to be critical 
at distinct points in development of the nervous system. Specifically, glioblastoma cancer 
stem cells preferentially require TFRC to propagate and form tumors in vivo.45 
MTHFD1L and PTRH2 are mitochondrial enzymes; while a role for these enzymes in 
glioblastoma biology has not been previously described, it has been reported that 
MTHFD1L confers metabolic advantages in hepatocellular carcinoma through its role in 
folate metabolism.46 S100A9 secreted protein has pro-inflammatory function,47 and 
S100A9 is part of a four-gene predictor of disease progression in human muscle invasive 
bladder cancer.48 While IGF2BP3 is an RNA-binding protein, evidence implicates it as 
an important mediator of tumor-stromal interactions, and expression of IGF2BP3 has 
been reported as a marker of poor survival and metastasis in multiple human 
malignancies.49-51  
Further evidence for the contribution of multiple biological processes to the 
predictive value of the ATE score comes from GO enrichment analysis of the extended 
set of genes that are highly correlated with signature genes in the TCGA glioblastoma 




mitotic cell cycle, nucleic acid binding, regulation of JNK signaling, mitochondria, 
myelination, and immune response. While mitotic cell cycle and nucleic acid binding are 
biologies readily relatable to tumor cell proliferation and response to current standard-of-
care treatment, the other terms identified point to potential roles for additional 
independent biological processes. Of note, identification of the GO term ‘immune 
response’ is consistent with strong expression of the ATE score in glioblastoma-
associated macrophages (Fig. 5B). In fact, expression of S100A9 appears to occur almost 
exclusively in macrophages associated with IDH wild-type glioblastomas. This contrasts 
sharply with expression of other ATE markers, including SOX11 and IGF2BP3, both of 
which appear to be largely confined to glioblastoma cells. Thus, it seems likely that both 
biological processes intrinsic to tumor cells and actions of stromal and immune 
components contribute to the predictive power of the ATE score. Further study is needed 
to determine which of the ATE marker genes are related to intrinsic properties of tumor 
aggressiveness and which might reflect response to the current standard of care or the 
role of other cell types in the tumor microenvironment.  
 
Conclusions 
The ATE score showed value in predicting prognosis within an IDH wild-type 
glioblastoma patient population representative of patients entering clinical trials in the 
United States and Europe. The signature is novel and can be measured in routine FFPE 
samples from diagnosis, making it easy to implement in clinical trials. As our discovery 




biological processes are associated with the nine signature genes, including response to 
DNA damage, tumor metabolism, regulation of neural differentiation, and tumor-stromal 
interactions. Future studies are required to further validate the prognostic and/or 
predictive effects of the signature. 
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Fig. 1 Elastic net (EN) penalized Cox proportional hazards regression from ATE datasets: (A) 
Pearson correlation between z-scored expression of each gene in the signature in the combined 
ATE dataset; (B, C) Kaplan–Meier plots for overall survival in the biomarker-evaluable 
population for the EN signature stratified by median, for all ATE cohorts together (B), and per 
trial (C). P-value corresponds to Cox proportional hazards model. Abbreviations: CI, confidence 
interval. HR, hazard ratio. 
 
Fig. 2 Kaplan–Meier plots for overall survival (OS) using the ATE score in the biomarker-
evaluable population, stratified by median: (A), ATE score only; (B) adjusted for MGMT 
promoter methylation status; and (C) adjusted for MGMT promoter methylation status and 
corticosteroid use at study entry. P-values calculated from log-rank test. Abbreviations: CI, 
confidence interval. HR, hazard ratio. MGMT, O-6-methylguanine-DNA methyltransferase gene. 
 
Fig. 3 Kaplan–Meier plots for overall survival (OS) using the ATE score in the biomarker-
evaluable population, stratified by median, adjusted for MGMT promoter methylation status when 
relevant: (A) AVAglio; (B) UCLA; and (C) GLARIUS (which enrolled patients with MGMT 
promoter non-methylated status only). P-values calculated from log-rank test. Abbreviations: CI, 
confidence interval. HR, hazard ratio. MGMT, O-6-methylguanine-DNA methyltransferase gene. 
UCLA, University of California, Los Angeles. 
 
Fig. 4 Forest plots showing multivariate Cox proportional hazard ratios with 95% confidence 
intervals and P-values for age, sex, surgical status, MGMT promoter methylation status, and ATE 
score in: (A) ATE; (B) AVAglio; (C) UCLA; and (D) GLARIUS. Corticosteroid use was also 




score. MGMT, O-6-methylguanine-DNA methyltransferase gene. N/A, not available. UCLA, 
University of California, Los Angeles. 
 
Fig. 5 (A) ATE score by MGMT promoter methylation status and Phillips subtype in: ATE, 
AVAglio,  UCLA, and GLARIUS; (B) ATE score calculated in individual cells isolated from 
adult glioblastoma tumors (n = 20) from study GSE13192836; (C) hierarchical clustering of 
average gene expression levels for the nine ATE signature genes in the four cell types identified 
in study GSE131928.36 Values indicate fraction of cells with detectable expression. 
Abbreviations: MGMT, O-6-methylguanine-DNA methyltransferase gene. UCLA, University of 
California, Los Angeles. 
